ABSTRACT
The SARS-CoV-2 virus activates maternal and placental immune responses, which in the setting of other infections occurring during pregnancy are known to impact fetal brain development. The effects of maternal immune activation on neurodevelopment are mediated at least in part by fetal brain microglia. However, microglia are inaccessible for direct analysis, and there are no validated non-invasive surrogate models to evaluate in utero microglial priming and function. We have previously demonstrated shared transcriptional programs between microglia and Hofbauer cells (HBCs, or fetal placental macrophages) in mouse models. Here, we assessed the impact of maternal SARS-CoV-2 on HBCs isolated from term placentas using single-cell RNA-sequencing. We demonstrated that HBC subpopulations exhibit distinct cellular programs, with specific subpopulations differentially impacted by SARS-CoV-2. Assessment of differentially expressed genes implied impaired phagocytosis, a key function of both HBCs and microglia, in some subclusters. Leveraging previously validated models of microglial synaptic pruning, we showed that HBCs isolated from placentas of SARS-CoV-2 positive pregnancies can be transdifferentiated into microglia-like cells, with altered morphology and impaired synaptic pruning behavior compared to HBC models from negative controls. These findings suggest that HBCs isolated at birth can be used to create personalized cellular models of offspring microglial programming.
Competing Interest Statement
R.H.P. has received fees for service as a scientific advisor to Belle Artificial Intelligence, Burrage Capital, Circular Genomics, Genomind, Swan Artificial Intelligence Studios, and Vault Health, outside of this work. A.G.E. serves as a consultant for Mirvie, Inc. and receives research funding from Merck Pharmaceuticals outside of this work. The other authors have no disclosures to report.
Funding Statement
NIH/NICHD: 1R01HD100022-01, 3R01HD100022-02S2, and 1U19AI167899-01 to A.G.E; 1K12HD103096 to L.L.S.; NIH/NIMH: 1RF1MH132336-01 to A.G.E. and R.H.P.; NIH: 5T32HG010464 to R.M.D.; B.A.G. was supported in part by the Geisel School of Medicine at Dartmouth's Center for Quantitative Biology by NIH/NIGMS: P20GM130454. J.Z.L. was supported by a grant from the Massachusetts Consortium for Pathogen Readiness (MassCPR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Mass General Brigham gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Sequencing data will be made available for download on GEO upon acceptance. R code supporting the conclusions of this manuscript is made available here: https://github.com/rbatorsky/covid-placenta-edlow.
